This list is an analysis based on recent market events. It's not an investment recommendation.
About
RxElite, Inc. is a pharmaceutical company that specializes in the development, production, and commercialization of generic prescription drugs, particularly within specialty markets. Its diverse product portfolio encompasses Sterile Liquid Dose offerings, such as generic ophthalmic solutions (available in both unit-dose and multi-dose formats), sterile unit-dose respiratory inhalation products, and various injectable medications. Beyond its finished drug products, the company, operating through its subsidiaries, also serves as a manufacturer of active pharmaceutical ingredients (APIs) for other pharmaceutical entities across the United States, Europe, and Asia. RxElite's extensive customer base includes institutional clients like hospitals and hospital group purchasing organizations, national and regional wholesale distributors, major direct retail pharmacy chains, home healthcare providers, and various outpatient surgery centers and ambulatory care clinics. The company maintains strategic alliances with industry partners such as Stason Pharmaceuticals, Inc., Alkem Laboratories Limited, and Zach Systems S.p.A. Headquartered in Meridian, Idaho, RxElite Inc. operates as a subsidiary of Piramal Healthcare Ltd.
The current price of RXEI is $0.00 USD — it has increased by +0% in the past 24 hours. Watch RXElite stock price performance more closely on the chart.
What is RXElite stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange RXElite stocks are traded under the ticker RXEI.
How many employees does RXElite have?▼
As of November 2, 2026, the company has 47 employees.
In which sector is RXElite located?▼
RXElite operates in the Health & Wellness sector.
When did RXElite complete a stock split?▼
The last stock split for RXElite was on July 17, 2007 with a ratio of 11.036789:1.
Where is RXElite headquartered?▼
RXElite is headquartered in Meridian, United States.